Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB) – Study VEL-2002 further validates solabegron’s potential for best-in-class efficacy across multiple primary and secondary endpoints Wayne, PA – March 28, 2019 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds […]
-Additional Funding to Advance Phase 2b Development Program in OAB- -Enrollment for Second Phase 2 Study Well Underway- -Issuance of U.S. Patent No. 10,065,922 Further Expands Velicept’s Portfolio Covering Solabegron- MALVERN, Pa.–(BUSINESS WIRE)–Velicept Therapeutics, a privately-held clinical stage pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, […]
-First study has begun enrolling patients to evaluate twice-daily formulation- -Second study to begin in the second quarter to assess once-daily dosing with the novel QD formulation- -Issuance of U.S. Patent No. 9,907,767 further expands Velicept’s patent portfolio covering Solabegron- MALVERN, PA – March 19, 2018 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated […]
Velicept Therapeutics, Inc. announced today Clarence Young, M.D. has joined its leadership team as the company’s Chief Medical Officer.
Malvern, PA, October 5, 2016 (BUSINESS WIRE) – Velicept Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application to initiate a Phase I pharmacokinetic study for a once-daily formulation for solabegron.